Gotowa bibliografia na temat „Vessie hyperactive”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Vessie hyperactive”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Vessie hyperactive"
Geoffrion, Roxana, Danny Lovatsis, Jens-Erik Walter, Queena Chou, William Easton, Annette Epp, Roxana Geoffrion i in. "Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie". Journal of Obstetrics and Gynaecology Canada 34, nr 11 (listopad 2012): 1102–4. http://dx.doi.org/10.1016/s1701-2163(16)35441-x.
Pełny tekst źródłaGeoffrion, Roxana. "Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie". Journal of Obstetrics and Gynaecology Canada 38, nr 12 (grudzień 2016): S158—S170. http://dx.doi.org/10.1016/j.jogc.2016.09.027.
Pełny tekst źródłaGeoffrion, Roxana. "N o 283-Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie". Journal of Obstetrics and Gynaecology Canada 40, nr 1 (styczeń 2018): e33-e44. http://dx.doi.org/10.1016/j.jogc.2017.11.006.
Pełny tekst źródłaBolduc, S., A. Fortin, V. Morin i P. Gervais. "P-032 – Observance au traitement chez les enfants atteints de vessie hyperactive". Archives de Pédiatrie 22, nr 5 (maj 2015): 241. http://dx.doi.org/10.1016/s0929-693x(15)30217-7.
Pełny tekst źródłaGeoffrion, Roxana. "N o 353 – Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie – Addenda". Journal of Obstetrics and Gynaecology Canada 39, nr 12 (grudzień 2017): 1230–39. http://dx.doi.org/10.1016/j.jogc.2017.08.042.
Pełny tekst źródłaZenner-Weber, Marietta. "Les symptômes d’urgence mictionnelle en cas de vessie hyperactive ont un retentissement considérable sur la qualité de vie". Revue Médicale Suisse 5, nr 196 (2009): 687. http://dx.doi.org/10.53738/revmed.2009.5.196.0687.
Pełny tekst źródłaLeon, P., A. Binet, C. Jolly i M. L. Poli-Merol. "Usage de la toxine botulique dans les vessies hyperactives non neurologiques chez l’enfant". Progrès en Urologie 22, nr 13 (listopad 2012): 758. http://dx.doi.org/10.1016/j.purol.2012.08.041.
Pełny tekst źródłaDenys, P., E. Chartier-Kastler, P. Azouvi, O. Remy-Neris i B. Bussel. "Effet urodynamique de la neurostimulation S3 test sur les vessies hyperactives résistantes des blessés médullaires". Annales de Réadaptation et de Médecine Physique 41, nr 6 (styczeń 1998): 348. http://dx.doi.org/10.1016/s0168-6054(98)80142-6.
Pełny tekst źródłaAmarenco, G., A. Le Cocquen, D. Lagauche, M. Chevignard i S. Bosc. "Étude cystomanométrique de 153 vessies neurologiques hyperactives avant et après test au bromure de prifinium". Annales de Réadaptation et de Médecine Physique 41, nr 7 (styczeń 1998): 417–20. http://dx.doi.org/10.1016/s0168-6054(98)80263-8.
Pełny tekst źródłaLardon, Renaud, i Alain Ruffion. "Quelles peuvent être les futures applications de la toxine botulique en urologie en dehors des vessies hyperactives des patients neurologiques ?" Progrès en Urologie - FMC 19, nr 3 (wrzesień 2009): F91—F94. http://dx.doi.org/10.1016/j.fpurol.2009.02.003.
Pełny tekst źródłaRozprawy doktorskie na temat "Vessie hyperactive"
Biardeau, Xavier. "Optimisation des thérapies de stimulation/modulation électrique dans le traitement des troubles vésico-sphinctériens neurogènes et non-neurogènes". Electronic Thesis or Diss., Université de Lille (2022-....), 2024. http://www.theses.fr/2024ULILS014.
Pełny tekst źródłaEven if it involves alternating between a filling phase and an emptying phase, the normal micturition cycle cannot be summed up as a binary operation but involves the constant consideration of multiple factors: the filling level of the bladder reservoir, the safety of the environment in which we live, the emotional context in which we evolve and the social constraints to which we are subjected.We now know that there are alterations and/or modifications in brain activity and connectivity, as well as changes in the regulation of the autonomic nervous system, in certain types of lower urinary tract dysfunction - notably in overactive bladder or urge urinary incontinence and in certain types of voiding dysfunctions. Among the therapies available today, electrical modulation/stimulation therapies (tibial neurostimulation and sacral neuromodulation) appear able to normalize and/or modify brain activity and connectivity, as well as ANS balance. They could thus provide at least a partial response to some of the etiopathogenies underlying these lower urinary tract dysfunctions. However, the deployment and positioning of these electrical modulation/stimulation therapies are still limited by an incomplete understanding of their mechanisms of action, imperfect identification of the indications and populations most likely to benefit from these therapies, a lack of consensus on the setting of the electrical current delivered, and a lack of medium and long-term evaluation. In the first part, we questioned the indications for these therapies, and particularly their place as a preventive approach for lower urinary tract dysfunctions due to spinal cord injury. We also questioned the relation, in terms of efficacy, between transcutaneous tibial neurostimulation and sacral neuromodulation, to better support patients in shared medical decision-making processe. Finally, we developed the first tool to predict the success of sacral neuromodulation as a treatment for voiding dysfunction. In the second part, we questioned the mechanisms of action, and more specifically the changes in the balance of the autonomic nervous system in response to an acute S3 sacral root stimulation.In the third part, we questioned the mid-term follow-up (5 years) after definitive implantation of sacral neuromodulation in a geographic population pool, looking for risk factors for discontinuation of follow-up. These data, although still to be supplemented by future research projects, will enable us to further optimize electrical modulation/stimulation therapies in the management of neurogenic and non-neurogenic lower urinary tract dysfunctions